

**More support for your patients:
Starting Taltz has never been easier
In PsA, AS, and nr-axSpA,
Taltz is the preferred IL-17A antagonist on 2 out of the
3 largest PBMs (Express Scripts NPF® and OptumRx®)¹**



Commercial Plan	Taltz in PsA, AS, and nr-axSpA
Express Scripts® National Preferred Formulary	Preferred IL-17A antagonist
Cigna® Commercial	Preferred IL-17A antagonist
OptumRx® Premium and Select Formularies	Preferred IL-17A antagonist

Part D Plan	Taltz in PsA, AS, and nr-axSpA
Express Scripts® Part D	Exclusive IL-17A antagonist
Cigna® Part D	Exclusive IL-17A antagonist
SilverScript® Plans	Exclusive IL-17A antagonist
Wellcare® Medicare Plans	Exclusive IL-17A antagonist
Aetna™ Medicare Plans	Exclusive IL-17A antagonist

Source: Data on File. Lilly USA, LLC. DOF-IX-US-0249. DOF-IX-US-0297, and is subject to change without notice by a healthplan or state. Please contact the plan or state for the most current information.

Please see additional formulary plan information on next page.

Taltz is **indicated** for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also **indicated** for patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Taltz is **contraindicated** in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Please see [Important Safety Information](#) on next page and accompanying full [Prescribing Information](#) and [Medication Guide](#). See [Instructions for Use](#) included with the device.



Important Safety Information

CONTRAINDICATIONS

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Infections

Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity

Serious hypersensitivity reactions, including angioedema and urticaria (each $\leq 0.1\%$), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Additional Formulary Information

This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.

Employers and employer groups may also offer additional benefit designs, which may be different than described.

This list may not be an exhaustive list of all plans in your area and the coverage of other plans in your area may vary.

Subject to contractual limitations, this list is not an exhaustive list of plans. If you do not see a specific Medicare Part D plan, please visit www.medicare.gov.

The company/plan names listed do not imply their endorsement of Lilly USA, LLC or the product(s) referenced.

Lilly USA, LLC does not endorse any particular plan. Other product and company names mentioned herein are the trademarks of their respective owners.

Reference:

1. Data on File. Lilly USA, LCC. DOF-IX-US-0249.

Inflammatory Bowel Disease

Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations

Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 1\%$) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please see accompanying full [Prescribing Information](#) and [Medication Guide](#). See [Instructions for Use](#) included with the device.

IX HCP ISI 07MAY2020